Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
TRIB
Trinity Biotech plc
Trinity Biotech plc (TRIB) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.3
/ 5.0
C
Value
C+
Factor Score
2.7
/ 5.0
Growth
C-
Factor Score
2.0
/ 5.0
Profitability
C-
Factor Score
2.0
/ 5.0
Momentum
C+
Factor Score
2.6
/ 5.0
Revisions
C-
Factor Score
2.0
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
0.0
EV / EBITDA
-6.1
Rev Growth YoY
-5.5%
Gross Margin
38.6%
Price Return 3M
1833.3%
Price Return 12M
1605.9%
Catalyst Signal
0.00
Market Cap
N/A
TTM Revenue
N/A
Price / Sales
0.2
ROE
N/M
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-03 | C+ (2.7) | C- (2.0) | C- (2.0) | C+ (2.6) | C- (2.0) | C (2.3) |